View as an RSS Feed
View JKenser's Articles BY TICKER:
Why Neuralstem Has Plenty Of Upside In The Short Term
- Neuralstem concluded dosing of Phase 2 NSI-566 trial for ALS (6-month observation concludes trial).
- Multiple late stage failures for ALS worth multiple times more than CUR.
- The market has given no value to Neuralstem's other indications.
An Early Valuation Of Neuralstem's NSI-189 For MDD
- Phase 1b shows early signs of safety and efficacy.
- Neurogenesis theory of depression could be "the next big thing in MDD".
- Market potential for NSI-189 is enormous and could grow exponentially with extraordinary results.
- An Early Valuation Of Neuralstem's NSI566